查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1402607

血管收缩素转化酵素（ACE）抑制剂市场：按药物、按适应症、按给药途径、按分销管道、按地区

Angiotensin Converting Enzymes Inhibitors Market, By Drugs, By Indication, By Route of Administration, By Distribution Channel, and By Region
出版日期: | 出版商: Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3个工作天内

价格
简介目录

血管收缩素转化酵素（ACE）抑制剂的全球市场规模预计将从2023年的80.705亿美元增加至2030年的118.317亿美元，2023-2030年预测期间复合年增长率为5.6%。

报告范围 报告详情
基准年 2022年 2023年市场规模 80.705 亿美元
实际资料 2018-2021 预测期 2023-2030
预测期复合年增长率 5.60% 2030年市场规模预测 118.317 亿美元
图 1. 2023 年按地区分類的血管收缩素转化酵素(ACE) 抑制剂的全球市场占有率(%)
血管紧张素转换酶抑制剂市场-IMG1

血管收缩素转化酵素（ACE）抑制剂是一类主要用于治疗高血压和心臟衰竭的药物。它透过抑制血管收缩素II 激素的作用发挥作用。血管收缩素II 会收缩血管并刺激另一种称为醛固酮的荷尔蒙的分泌，导致体内水分和盐分储存。 ACE抑制剂阻断血管收缩素II的产生，血管紧张素II可以放鬆和扩张血管，减少体内保留的水量，并降低血压。常用的 ACE 抑制剂包括赖诺普利、Enalapril和雷米普利。副作用包括干咳、头晕和肾臟损伤。对于服用 ACE 抑制剂的人来说，定期检查以监测肾功能和钾水平非常重要。 ACE 抑制剂透过调节血管收缩素II 的作用并帮助血管放鬆和扩张，同时调节液体储存，发挥至关重要的作用，从而显着降低血压。

市场动态

全球血管收缩素转化酵素（ACE）抑制剂市场的成长是由全球高血压和心臟病的高盛行率所推动的。身体产生四种激素，称为血管收缩素（an-gee-oh-ten-sin，类型名称为罗马数字）。血管收缩素I经由ACE转化为血管收缩素II，具有多种物理作用。通常建议使用 ACE 抑制剂，特别是对于心血管疾病和高血压。 2019 年，超过 1,290 万名 Medicare D 部分用户（约占所有 D 部分受益人的 27%）接受了 ACE 抑制剂。 ACE抑制剂确实会引起不良反应。大多数是轻微的，但少数是危险的，需要紧急医疗护理。

本研究的主要特点

  • 本报告对全球血管收缩素转化酵素（ACE）抑制剂市场进行了详细分析，并提供了以2022年为基准年的预测期（2023-2030）的市场规模和年复合成长率（CAGR%）。 。
  • 它还阐明了各个细分市场的潜在商机，并解释了该市场有吸引力的投资提案矩阵。
  • 它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
  • 根据公司亮点、产品系列、主要亮点、业绩和策略等参数，对全球血管收缩素转化酵素(ACE) 抑制剂市场的主要参与者进行了分析。
  • 该报告的见解使行销人员和公司负责人能够就未来的产品发布、升级、市场扩张和行销策略做出明智的决策。
  • 全球血管收缩素转化酵素(ACE) 抑制剂市场报告迎合了该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
  • 相关人员可以透过分析全球血管收缩素转化酵素(ACE) 抑制剂市场时使用的各种策略矩阵来促进他们的决策。

目录

第一章 研究目的与前提

  • 研究目标
  • 先决条件
  • 简称

第二章 市场展望

  • 报告说明
    • 市场定义和范围
  • 执行摘要
  • Coherent Opportunity Map（COM）

第三章市场动态、法规及趋势分析

  • 市场动态
    • 促进因素
  • 高血压盛行率上升
  • 不断成长的研发活动
  • 提高心血管健康意识
    • 抑制因素
  • 专利到期日
  • 副作用和安全问题
  • 副作用和安全问题
    • 机会
  • 提高心血管健康意识
  • 个人化医疗
  • 联合治疗
  • 影响分析
  • 主要亮点
  • 监管场景
  • 产品发布/核准
  • PEST分析
  • 波特的分析
  • 併购场景

第四章全球血管收缩素转化酵素(ACE) 抑制剂市场 –冠状病毒(COVID-19) 大流行的影响

  • 新型冠状病毒感染疾病（COVID-19）的流行病学
  • 供需面分析
  • 经济影响

第五章全球血管收缩素转化酵素（ACE）抑制剂市场（按药物），2018-2030

  • 贝那普利
  • 培哚普利
  • 川福普利
  • Captopril
  • Enalapril
  • 赖诺普利
  • 其他（雷米普利等）

第六章 2018-2030 年全球血管收缩素转化酵素(ACE) 抑制剂市场（依适应症）

  • 高血压
  • 冠状动脉疾病
  • 心臟衰竭
  • 慢性肾臟病
  • 硬皮症
  • 其他（偏头​​痛等）

第 7 章全球血管收缩素转化酵素(ACE) 抑制剂市场，依给药途径，2018-2030 年

  • 口服
  • 可注射的

第8章2018-2030年全球血管收缩素转化酵素（ACE）抑制剂市场（依通路）

  • 医院药房
  • 零售药房
  • 网路药房

第9章2018-2030年全球血管收缩素转化酵素（ACE）抑制剂市场（按地区）

  • 北美洲
  • 美国
  • 加拿大
  • 欧洲
  • 英国
  • 德国
  • 义大利
  • 法国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
  • 中东和非洲
  • GCC
  • 以色列
  • 北非
  • 中部非洲
  • 其他中东和非洲

第10章竞争形势

  • Novartis AG
  • Pfizer Inc.
  • Merck & Co.
  • AstraZeneca
  • Sanofi
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Lupin Limited
  • Torrent Pharmaceuticals Ltd.
  • Reddy's Laboratories Ltd.
  • Mylan

第11章 章节

  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI2746

The global angiotensin converting enzymes (ACE) inhibitors market size is projected to reach US$ 11,831.7 million by 2030, from US$ 8,070.5 million in 2023, at a CAGR of 5.6% during the forecast period 2023-2030.

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 8,070.5 Mn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 5.60% 2030 Value Projection: US$ 11,831.7 Mn
Figure 1. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market Share (%), By Region, 2023
Angiotensin Converting Enzymes Inhibitors Market - IMG1

Angiotensin converting enzymes (ACE) inhibitors are a type of medication used primarily in the treatment of high blood pressure and heart failure. They work by blocking the action of a hormone called angiotensin II. Angiotensin II causes blood vessels to constrict and promotes the release of another hormone called aldosterone, which leads to water and salt retention in the body. By inhibiting the production of angiotensin II, ACE inhibitors help to relax and widen the blood vessels, reduce the amount of water retained by the body, and therefore lower blood pressure. Commonly prescribed ACE inhibitors include lisinopril, enalapril, and ramipril. Side effects can include dry cough, dizziness, and kidney problems. It is important for individuals taking ACE inhibitors to have regular check-ups to monitor their kidney function and potassium levels. ACE inhibitors play a pivotal role in mitigating the effects of angiotensin II, aiding in the relaxation and widening of blood vessels while regulating fluid retention, thus contributing significantly to blood pressure reduction.

Market Dynamics

The global angiotensin converting enzymes (ACE) inhibitors market's growth is driven by the high prevalence of hypertension and heart disease globally. The body produces four distinct forms of the hormone angiotensin (an-gee-oh-ten-sin; the types' names are Roman numerals). Angiotensin I is converted to angiotensin II by ACE, which has a variety of bodily consequences. ACE inhibitors are often recommended, particularly for cardiovascular diseases and high blood pressure. An ACE inhibitor was given to over 12.9 million Medicare Part D participants in 2019 (or roughly 27% of all beneficiaries with Part D coverage). It is true that ACE inhibitors can cause negative effects. Most of them are mild, but a few are dangerous and require emergency medical attention.

Key features of the study:

  • This report provides in-depth analysis of the global angiotensin converting enzymes (ACE) inhibitors market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global angiotensin converting enzymes (ACE) inhibitors market based on the following parameters-company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Novartis AG, Pfizer Inc., Merck & Co., AstraZeneca, Sanofi, Boehringer Ingelheim, GlaxoSmithKline, Lupin Limited, Torrent Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Mylan and Other Prominent Players
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global angiotensin converting enzymes (ACE) inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global angiotensin converting enzymes (ACE) inhibitors market

Detailed Segmentation:

  • Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Drugs:
    • Benazepril
    • Perindopril
    • Trandfolapril
    • Captopril
    • Enalapril
    • Lisinopril
    • Others (Ramipril, etc.)
  • Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Indication:
    • Hypertension
    • Coronary Artery Disease
    • Heart Failure
    • Chronic Kidney Disease
    • Scleroderma
    • Others (Migraine, etc.)
  • Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Route of Administration:
    • Oral
    • Injectable
  • Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East &Africa
  • Company Profiles:
    • Novartis AG
    • Pfizer Inc.
    • Merck & Co.
    • AstraZeneca
    • Sanofi
    • Boehringer Ingelheim
    • GlaxoSmithKline
    • Lupin Limited
    • Torrent Pharmaceuticals Ltd.
    • Reddy's Laboratories Ltd.
    • Mylan
    • Other Prominent Players

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Drugs
    • Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Indication
    • Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Route of Administration
    • Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Distribution Channel
    • Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
  • Rising prevalence of hypertension
  • Growing Research and Development Activities
  • Increasing Awareness of Cardiovascular Health
    • Restraints
  • Patent Expirations
  • Side Effects and Safety Concerns
  • Side Effects and Safety Concerns
    • Opportunities
  • Increasing Awareness of Cardiovascular Health
  • Personalized medicine
  • Combination therapies
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product Launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Drugs, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Benazepril
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Perindopril
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Trandfolapril
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Captopril
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Enalapril
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Lisinopril
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Others (Ramipril, etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

6. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Indication, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Hypertension
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn )
  • Coronary Artery Disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn )
  • Heart Failure
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn )
  • Chronic Kidney Disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn )
  • Scleroderma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Others (Migraine, etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)

7. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Route of Administration, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Injectable
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

8. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Distribution Channel, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

9. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Region, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Region, 2019 -2030
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East & Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018-2030, (US$ Mn)
  • GCC
  • Israel
  • North Africa
  • Central Africa
  • Rest of Middle East & Africa

10. Competitive Landscape

  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Pfizer Inc.
  • Merck & Co.
  • AstraZeneca
  • Sanofi
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Lupin Limited
  • Torrent Pharmaceuticals Ltd.
  • Reddy's Laboratories Ltd.
  • Mylan
  • Analyst Views

11. Section

  • Research Methodology
  • About us